In vivo RNAi delivery
Monday, 16 February, 2009
Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
Invitrogen
www.invitrogen.com/invivornai
'Directed evolution' used to design molecules in mammal cells
Scientists have developed a system that uses so-called 'biological artificial...
Novel drug candidates found for nerve pain and ischemic disease
The discovery paves the way for potential new treatments for health conditions linked to tissue...
Real-time sequencing helps combat golden staph infections
Tracking bacterial changes during serious Staphylococcus aureus (golden staph) infection...
